US OptionsDetailed Quotes
NVAX241101P12000
- 2.22
- +0.07+3.26%
15min DelayClose Oct 31 16:00 ET
2.22High2.22Low
2.22Open2.15Pre Close3 Volume139 Open Interest12.00Strike Price666.00Turnover0.00%IV-1.77%PremiumNov 1, 2024Expiry Date2.39Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.06Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Novavax Stock Discussion
Sign in to post a comment
$Novavax (NVAX.US)$ drop to 5, come on!!
2
Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...
+20
13
after week 1 my position...
I was told I need ensure to be on a increasing positive trend each week.
bought 2 steady etf. trying gold etf which seems to be on uptrend.
other gainers include $Palantir (PLTR.US)$ $Novavax (NVAX.US)$.
losers currently $On Holding (ONON.US)$ $NIO Inc (NIO.US)$ $XPeng (XPEV.US)$ hope they make a recovery next week.
seems like everyone playing penny pharma, me too in $60 Degrees Pharmaceuticals (SXTP.US)$ but the challenge don't allow us to buy stock below 1usd.
I was told I need ensure to be on a increasing positive trend each week.
bought 2 steady etf. trying gold etf which seems to be on uptrend.
other gainers include $Palantir (PLTR.US)$ $Novavax (NVAX.US)$.
losers currently $On Holding (ONON.US)$ $NIO Inc (NIO.US)$ $XPeng (XPEV.US)$ hope they make a recovery next week.
seems like everyone playing penny pharma, me too in $60 Degrees Pharmaceuticals (SXTP.US)$ but the challenge don't allow us to buy stock below 1usd.
4
$Novavax (NVAX.US)$ just a blip based on one event that I can’t see is linked to their vaccine. When FDA gives the green light to start again - expect a huge rebound that may take it to at least 14. Influenza vaccination is a huge area, and combined with COVID-19, this will be huge
4
$Novavax (NVAX.US)$ why stay at 10? Go down to 5. Drop more, useless stock.
The market climbed Wednesday, and the Dow closed at a high while big tech companies competed for the largest power supply for AI. Morgan Stanely and United's earnings kept the S&P 500 within 50 points of a trading high, but consumer tech was pulling back after Apple nearly hit an all-time high Tuesday.
Just past the 4 pm ET Wednesday close, the $S&P 500 Index (.SPX.US)$ traded +0.48%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0...
Just past the 4 pm ET Wednesday close, the $S&P 500 Index (.SPX.US)$ traded +0.48%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0...
56
15
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Good morning, traders. Happy Wednesday, October 16th. The market is climbing, and big tech companies are competing to amass the largest power supply for AI.
My name is Kevin Travers; here's the top news today for your daily trades.
$United Airlines (UAL.US)$ was the highest gainer on the S&P 500, up about 9% after the airline posted a strong demand and higher revenue for its Tuesday night Q3 report and earnings above estimates.
$Morgan Stanley (MS.US)$ climbed 7...
My name is Kevin Travers; here's the top news today for your daily trades.
$United Airlines (UAL.US)$ was the highest gainer on the S&P 500, up about 9% after the airline posted a strong demand and higher revenue for its Tuesday night Q3 report and earnings above estimates.
$Morgan Stanley (MS.US)$ climbed 7...
58
24
$Novavax (NVAX.US)$ entry point now
1
Here are the levels to watch on this drop. The GAP at 8.61 is in play if it trends down today was already tested PM.
Larger Image: tradingview.com...
$Novavax (NVAX.US)$
Larger Image: tradingview.com...
$Novavax (NVAX.US)$
2
No comment yet
Stock Winner : No
Dafydd Green : That won’t happen. The recent slump is to do with one FDA pause on a trial - and is very likely to restart again soon. The restart will cause a price surge and draw attention again to its influenza portfolio - which is strong. Bears, I don’t think there’s much left to squeeze here